ADMA Biologics(US:ADMA)2026-02-25 22:32Financial Data and Key Metrics Changes - Total revenue for 2025 was $510 million, representing a 20% year-over-year growth [5][14] - Adjusted EBITDA reached $231 million, increasing 40% year-over-year [5][14] - Adjusted net income totaled $161 million, reflecting a 35% year-over-year increase [5][14] - Gross margin expanded to 57.4% from 51.5% in 2024, driven by Asceniv's growing contribution [14] Business Line Data and Key Metrics Changes - Asceniv achieved $363 million in net revenue for 2025, representing a 51% year-over-year growth [7] - The company expects Asceniv to continue driving growth, with a projected 70-30 revenue split between Asceniv and Bivigam in 2025 [30] Market Data and Key Metrics Changes - The company anticipates total revenue to exceed $635 million in 2026 and $775 million in 2027, with significant contributions from Asceniv [16][17] - The U.S. immunoglobulin market is expected to grow, providing a favorable environment for Asceniv's continued penetration [22] Company Strategy and Development Direction - The company is focused on driving commercial execution, investing in a capital-efficient pipeline, and maintaining balance sheet discipline [11][12] - Strategic repositioning of the plasma collection network aims to enhance capital efficiency and secure long-term supply visibility [9][23] - The lead pipeline asset, SG-001, is expected to represent a significant long-term revenue opportunity, with a pre-IND package submission anticipated in 2026 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position entering 2026, highlighting strong demand and improved margins [22][18] - The integration of yield-enhanced production is expected to support gross margin growth and increased cash generation [9][18] Other Important Information - The company announced a leadership transition with Terry-Ann Kohler appointed as the new CFO, succeeding Brad Tade [11][19] - The company maintains a healthy balance sheet with $88 million in cash at the end of 2025 [15] Q&A Session Summary Question: Update on Asceniv's role in product mix and revenue guidance - Management indicated a 70-30 split between Asceniv and Bivigam in 2025, with expectations for continued growth in Asceniv's contribution [30][32] Question: Update on third-party supply contracts for RSV plasma - Management confirmed ongoing performance of third-party supply agreements and plans for expansion, adding about 30 centers today with projections for 50 additional centers [34][36] Question: Expectations for new immunology centers and prescriber base growth in 2026 - Management actively calls on about 300 immunologists and expects to grow both reach and depth in existing institutions, contributing to revenue growth [41][43] Question: Timeline for McKesson's impact on receivables - Management anticipates seeing McKesson's impact in the first half of the year, with normalization of accounts receivable expected by mid to late 2026 [46][48]